High-dose Ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia.
Lie
S O
SO
Dept. of Pediatrics, Rikshospitalet, Oslo, Norway.
Berglund
G
G
Gustafsson
G
G
Jonmundsson
G
G
Siimes
M
M
Yssing
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D003561:Cytarabine / Q000008:administration & dosage*; D004314:Down Syndrome / Q000150:complications; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007055:Iceland / Q000453:epidemiology; D007223:Infant; D007231:Infant, Newborn; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015993:Life Tables; D015337:Multicenter Studies as Topic; D011289:Preleukemia / Q000453:epidemiology; D012074:Remission Induction; D012537:Scandinavian and Nordic Countries / Q000453:epidemiology; D015996:Survival Rate; D013866:Thioguanine / Q000008:administration & dosage
D003561:Cytarabine; D004317:Doxorubicin; D013866:Thioguanine